Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927994 | 1.00 | TLR2 (0.49) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL30973621 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM4TP53MDM2 | |
| SCHEMBL25845385 | 0.89 | TLR2 (0.54) | TLR2KMT2AMDM4TP53MDM2 | |
| SCHEMBL12231705 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM4TP53MDM2 | |
| SCHEMBL463455 | 0.89 | TLR2 (0.50) | TLR2KMT2AMDM4TP53MDM2 | |
| SCHEMBL18709106 | 0.88 | TLR2 (0.49) | TLR2KMT2AMDM4TP53MDM2 | |
| SCHEMBL23927986 | 0.88 | TLR2 (0.59) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL23927982 | 0.88 | TLR2 (0.59) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL23447188 | 0.87 | TLR2 (0.56) | TLR2KMT2ACASP3MDM4TP53 | |
| SCHEMBL29083323 | 0.87 | TLR2 (0.43) | TLR2KMT2ACASP3MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMA (US) | 2024-12-12 | — | — | US | disclosed |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2021-10-28 | — | — | US | disclosed |
| CN-111601619-A | Hydrophilic linkers for antibody drug conjugates | 里珍纳龙药品有限公司 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332080-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | TLR2 2327/4885KMT2A 936/4885CASP3 3829/4885 |
| US-12134631-B2 | Hydrophilic linkers for antibody drug conjugates | CD44, CD47, EPCAM | TLR2 2327/4885KMT2A 936/4885CASP3 3829/4885 |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | TLR2 2327/4885KMT2A 936/4885CASP3 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.